Significance of T-Cell Subsets for Clinical Response to Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B Patients

References

• Zhang W, Chen J, Wu M, et al. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology. 2017;66(2):398–415.
   PubMed Web of Science ®Google Scholar
• Wang S, Chen Z, Hu C, et al. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. Journal of Immunology. 2013;190(10):5142–5151.
   PubMed Web of Science ®Google Scholar
• Wu M, Wang C, Shi B, et al. A novel recombinant cccDNA-based mouse model with long term maintenance of rcccDNA and antigenemia. Antiviral Res. 2020;180:104826.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang X, Chen L, et al. Circulating miR-210 and miR-22 combined with ALT predict the virological response to interferon-alpha therapy of CHB patients. Sci Rep. 2017;7(1):15658.
   PubMedGoogle Scholar
• Zhang X, Chen C, Wu M, et al. Plasma microRNA profile as a predictor of early virological response to interferon treatment in chronic hepatitis B patients. Antivir Ther. 2012;17(7):1243–1253.
   PubMed Web of Science ®Google Scholar
• Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135(2):459–467.
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–129.
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–2695.
   PubMed Web of Science ®Google Scholar
• Chon YE, Kim DJ, Kim SG, et al. An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study. Medicine. 2016;95(14):3026.
   PubMed Web of Science ®Google Scholar
• Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56(5):699–705.
   PubMed Web of Science ®Google Scholar
• Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137(6):2002–2009.
   PubMed Web of Science ®Google Scholar
• Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17(6):643–650.
   PubMed Web of Science ®Google Scholar
• Tujios SR, Lee WM. Update in the management of chronic hepatitis B. Curr Opin Gastroenterol. 2013;29(3):250–256.
   PubMed Web of Science ®Google Scholar
• Yang S, Xing H, Wang Y, et al. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients. Virol J. 2016;13(1):016–0640.
   PubMedGoogle Scholar
• Mao QG, Pan JS, Fang KN, et al. Precise prediction model and simplified scoring system for sustained combined response to interferon-alpha. World j Gastroenterol. 2010;16(27):3465–3471.
   PubMed Web of Science ®Google Scholar
• Peng G, Li S, Wu W, et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008;45(4):963–970.
   PubMed Web of Science ®Google Scholar
• Park JJ, Wong DK, Wahed AS, et al. Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology. 2016;150(3):684–695.
   PubMed Web of Science ®Google Scholar
• Boni C, Fisicaro P, Valdatta C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81(8):4215–4225.
   PubMed Web of Science ®Google Scholar
• Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology. 2010;138(2):682–693.
   PubMed Web of Science ®Google Scholar
• Chen J, Wang XM, Wu XJ, et al. Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res. 2011;60(1):47–53.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242.
   PubMed Web of Science ®Google Scholar
• Raziorrouh B, Schraut W, Gerlach T, et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology. 2010;52(6):1934–1947.
   PubMed Web of Science ®Google Scholar
• Mohammadizad H, Shahbazi M, Hasanjani Roushan MR, et al. TIM-3 as a marker of exhaustion in CD8(+) T cells of active chronic hepatitis B patients. Microb Pathog. 2019;128:323–328.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Jayaraman P, Behar SM, et al. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32(8):345–349.
   PubMed Web of Science ®Google Scholar
• Feng C, Cao LJ, Song HF, et al. Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters. Viral Immunol. 2015;28(8):418–424.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang G, Wang F, et al. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol. 2017;5(4):297–318.
   PubMed Web of Science ®Google Scholar
• Park JJ, Wong DK, Wahed AS, et al. Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology. 2016;150(3):684–695 e685.
   PubMed Web of Science ®Google Scholar
• Schurich A, Pallett LJ, Lubowiecki M, et al. The third signal cytokine IL-12 rescues the antiviral function of exhausted HBV-specific CD8 T cells. PLoS Pathog. 2013;9(3):14.
   Web of Science ®Google Scholar
• Maier H, Isogawa M, Freeman GJ, et al. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. Journal of Immunology. 2007;178(5):2714–2720.
   PubMed Web of Science ®Google Scholar
• Zhang E, Zhang X, Liu J, et al. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection. PLoS One. 2011;6(10):14.
   Web of Science ®Google Scholar
• Fisicaro P, Valdatta C, Massari M, et al. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology. 2012;143(6):1576–1585.
   PubMed Web of Science ®Google Scholar
• Gane EJ. Future anti-HBV strategies. Liver International. 2017;1:40–44.
   Google Scholar
• Cox MA, Nechanitzky R, Mak TW. Check point inhibitors as therapies for infectious diseases. Curr Opin Immunol. 2017;48:61–67.
   PubMed Web of Science ®Google Scholar
• Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study. J Hepatol. 2019;71(5):900–907.
   PubMed Web of Science ®Google Scholar
• Sung PS, Park DJ, Kim JH, et al. Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8(+) T Cells in Patients Considered Immune Tolerant. Front Immunol. 2019;10:1319.
   PubMed Web of Science ®Google Scholar
• Mühlbauer M, Fleck M, Schütz C, et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol. 2006;45(4):520–528.
   PubMed Web of Science ®Google Scholar
• Liu L, Hou J, Xu Y, et al. PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response. PLoS One. 2020;15(7):e0228302.
   PubMed Web of Science ®Google Scholar
• Ma L, Cai YJ, Yu L, et al. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013;57(3):1304–1311.
   PubMed Web of Science ®Google Scholar
• Xu P, Chen YJ, Chen H, et al. The expression of programmed death-1 in circulating CD4+ and CD8+ T cells during hepatitis B virus infection progression and its correlation with clinical baseline characteristics. Gut Liver. 2014;8(2):186–195.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao C, Peng Q, et al. Expression levels of CD28, CTLA-4, PD-1 and Tim-3 as novel indicators of T-cell immune function in patients with chronic hepatitis B virus infection. Biomedical Rep. 2014;2(2):270–274.
   PubMedGoogle Scholar
• Craxi A, Cooksley WG. Pegylated interferons for chronic hepatitis B. Antiviral Res. 2003;60(2):87–89.
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus Adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44(3):675–684.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128(7):1890–1897.
   PubMed Web of Science ®Google Scholar
• Jansen L, de Niet A, Makowska Z, et al. An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B. Liver International. 2015;35(7):1824–1832.
   PubMed Web of Science ®Google Scholar
• Wang YC, Yang SS, Su CW, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep. 2016;6:29605.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52(4):1251–1257.
   PubMed Web of Science ®Google Scholar